Accelerate Polpharma Biologics biosimilar program from IND to commercial manufacturing
Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, is pleased to announce a strategic cooperation agreement with Polpharma Biologics to advance the end-to-end development and manufacture of a biosimilar product for the global market. This partnership underscores Chime Biologics’ commitment to delivering high-quality, cost-effective biologics and further strengthening Chime Biologics’ presence in Europe.
Under this agreement, Chime Biologics will provide Polpharma Biologics with end-to-end support for a biosimilar development, spanning from investigational new drug (IND) to commercial supply.
Health Technology Insights: Macrium, Sysmex America Partner to Reduce Testing Downtime
Meeting Global Supply Needs
Polpharma Biologics, a major player in the global biosimilar market and the largest biotechnology company in Poland, brings a robust pipeline that includes multiple early-stage and late-stage biosimilars, along with two FDA/EMA-approved biosimilar products.
With an extensive track record in delivering biosimilars for global markets, Chime Biologics is well-positioned to meet the growing global demand for biosimilars. Through Chime’s true end-to-end offerings, from our state-of-the-art cell line, process and analytical development capabilities, expanding manufacturing capabilities and regulatory support activities, Chime Biologics offers clients fast-tracked CMC development to commercial supply to ensure fast market entry for our clients.
Health Technology Insights: 8 in 10 Nursing Leaders Pilot New Care Models, Says Survey
“We are thrilled to contribute to Polpharma Biologics’ growth as we provide all-in-one solutions to accelerate biosimilar development and reduce the time-to-market,” said Dr. Jimmy Wei, President of Chime Biologics. “This collaboration reinforces our strategy of delivering high-quality, affordable biologics to patients worldwide.”
“Partnering with Chime Biologics supports our strategic vision to swiftly bring affordable biosimilars developed in Europe to global markets,” said Konstantin Matentzoglu, Member of the Supervisory Board of Polpharma Biologics Group BV. “By working with Chime Biologics, we can accelerate patient access to biosimilar therapies. This partnership further strengthens Polpharma Biologics’ global position as a leading biosimilars developer, while leveraging Asian partners with optimized cost-benefit ratio”.
Health Technology Insights: Illumina, Tempus Partner to Advance Genomic AI in Medicine
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
